Allogene Therapeutics, Inc.

ALLO

Allogene Therapeutics, Inc.

ALLO

Insider Sentiment (TTM):

Last Purchase:2024-05-16Last Sale:2026-04-21Shares Purchased (TTM):0Shares Sold (TTM):325,568

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:176,242,800Shares Outstanding:240,290,782Institutional Ownership Pct.:73.35%

Earnings Market Reaction:

Filing Date:2026-08-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	39	30	52	38	52	42	75	51	171	51	83	69
Available For Sale Securities Debt Securities Curr…	294	237	199	214	221	238	217	240	274	334	366	396
Prepaid Expense And Other Assets Current	7	6	8	9	10	12	11	13	12	11	10	8
Assets Current	340	273	258	261	283	292	303	304	457	395	459	473
Available For Sale Securities Debt Securities Nonc…	91	0	8	25	30	56	81	112	-	12	0	32
Operating Lease Right Of Use Asset	38	39	40	41	42	44	45	46	58	64	64	79
Property Plant And Equipment Net	67	70	73	76	79	83	86	89	92	96	99	103
Escrow Deposit	0	0	23	23	23	22	21	22	21	-	0	-
Restricted Cash Noncurrent	10	10	10	10	10	10	10	10	10	10	10	10
Other Assets Noncurrent	4	4	4	4	4	2	2	5	6	5	7	10
Assets	550	396	416	440	471	508	549	589	647	586	643	712
Investments In Affiliates Subsidiaries Associates …	-	-	-	-	-	-	0	0	1	3	4	5
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	6	5	4	4	5	5	5	6	13	6	6	6
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	0	0	0
Liabilities Current	32	28	33	32	32	30	36	33	37	31	37	38
Operating Lease Liability Noncurrent	70	73	75	77	79	81	83	85	87	89	88	90
Other Liabilities Noncurrent	12	16	16	15	15	11	8	8	8	5	5	1
Liabilities	114	117	123	124	126	123	127	125	132	125	131	129
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	2,532	2,332	2,303	2,287	2,275	2,265	2,242	2,223	2,209	2,089	2,075	2,059
Retained Earnings Accumulated Deficit	-2,096	-2,053	-2,011	-1,972	-1,930	-1,880	-1,820	-1,760	-1,694	-1,627	-1,562	-1,474
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	0	0	-0	0	-0	0	-1	-1	-1	-2
Stockholders Equity	436	279	293	315	345	385	422	464	515	461	512	581
Liabilities And Stockholders Equity	550	396	416	440	471	508	549	589	647	586	643	712
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0	0.001	0.001	0.001	0	0.001	0.001	0.001	0	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	400	400	400	400	400	400	400	400	400	400	400	400
Common Stock Shares Issued	345	245	229	223	220	219	212	210	209	170	169	168
Shares Outstanding	345	245	229	223	220	219	212	210	209	170	169	168

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-19.31%	-10.73%	-15.45%	-	-	-	-	-	-	-	-	-
2025	25.66%	5.31%	-4.42%	10.58%	27.88%	19.23%	39.05%	31.43%	63.81%	0.40%	-12.96%	-12.15%
2024	-20.00%	-26.90%	-11.38%	6.48%	17.81%	-1.21%	-22.26%	-31.35%	-39.18%	-23.81%	-10.05%	-38.10%
2023	-	-	-	-	-	-	-4.38%	3.03%	4.04%	-12.00%	-31.78%	-44.44%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	10.72	9.65	7.93	8.19	8.92	9.71	8.54	9.35	12.25	12.80	12.38	12.58
Quick Ratio	10.48	9.42	7.70	7.92	8.62	9.33	8.23	8.95	11.92	12.46	12.10	12.37
Working Capital	308.27M	244.96M	225.24M	228.89M	250.98M	261.55M	267.86M	271.84M	419.82M	364.47M	422.04M	435.82M
Leverage & Debt
Debt to Equity	0.26	0.42	0.42	0.39	0.37	0.32	0.30	0.27	0.26	0.27	0.25	0.22
Interest Coverage TTM	-138.71	-155.28	-194.71	-269.75	-424.50	-50.55	-52.85	-58.53	-57.95	-78.92	-86.75	-89.75
Debt Ratio	0.21	0.30	0.30	0.28	0.27	0.24	0.23	0.21	0.20	0.21	0.20	0.18
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.50	-0.72	-0.87	-0.95	-1.08	-1.17	-1.32	-1.35	-1.47	-1.73	-2.09	-2.05
Free Cash Flow Per Share TTM	-0.43	-0.46	-0.68	-0.48	-0.55	-0.92	-1.03	-1.04	-1.20	-1.35	-1.52	-1.49
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-1,241,813.64%	-692,600.00%	-444,676.92%	-342,700.00%	-344,986.32%	-997,320.59%
Net Profit Margin TTM	-	-	-	-	-	-	-1,170,863.64%	-659,137.21%	-429,881.54%	-335,973.56%	-344,489.47%	-1,012,105.88%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-76.84%	26.47%	6.56%	-30.40%	-39.10%	-99.96%
Net Income Growth (1Y)	-30.14%	-31.14%	-25.90%	-25.20%	-15.22%	-13.68%	-21.29%	-17.64%	-23.44%	-18.93%	-3.86%	44.77%
EPS Growth (1Y)	-53.51%	-38.28%	-34.57%	-29.53%	-26.41%	-32.21%	-36.59%	-33.99%	-40.86%	-30.70%	-12.31%	24.06%
Valuation Metrics
P/E TTM	-4.13	-3.37	-1.58	-1.30	-1.04	-1.25	-1.61	-2.07	-1.58	-2.59	-1.54	-1.54
P/B TTM	1.57	2.10	1.03	0.87	0.72	0.82	0.98	1.26	0.86	1.64	0.98	0.92
P/S TTM	-	-	-	-	-	-	18,861.32	13,621.58	6,811.72	8,689.70	5,302.64	15,630.81
Market Cap	684.17M	586.31M	302.25M	275.33M	247.39M	314.42M	414.95M	585.73M	442.76M	756.00M	503.75M	531.45M
Enterprise Value	635.26M	545.71M	240.27M	227.22M	184.77M	261.68M	329.44M	524.20M	261.80M	694.67M	410.30M	451.91M
Calculated Values
Free Cash Flow TTM	-142.70M	-109.64M	-149.74M	-106.07M	-120.68M	-198.12M	-200.99M	-217.93M	-228.93M	-227.48M	-239.25M	-249.15M
Net Debt	-48.92M	-40.60M	-61.98M	-48.11M	-62.62M	-52.75M	-85.51M	-61.53M	-180.96M	-61.33M	-93.45M	-79.54M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-21Sale

Owner: Yoshiyama, Annie

Title: SVP, Finance

Shares: 9,586

Price/Share: $2.31

Value: $22,143.66

Shares Owned: 124,517

Relationship: Officer

Ownership: Direct

2026-03-31Sale

Owner: Beneski, Benjamin Machina…

Title: SVP, Chief Technical Officer

Shares: 2,867

Price/Share: $2.50

Value: $7,167.50

Shares Owned: 195,338

Relationship: Officer

Ownership: Direct

2026-03-16Sale

Owner: Beneski, Benjamin Machina…

Title: SVP, Chief Technical Officer

Shares: 4,835

Price/Share: $2.47

Value: $11,942.45

Shares Owned: 198,205

Relationship: Officer

Ownership: Direct

2026-03-16Sale

Owner: Chang, David D

Title: President and CEO

Shares: 47,763

Price/Share: $2.47

Value: $117,974.61

Shares Owned: 5,150,599

Relationship: Director,Officer

Ownership: Direct

2026-03-02Sale

Owner: Beneski, Benjamin Machina…

Title: SVP, Chief Technical Officer

Shares: 7,132

Price/Share: $2.60

Value: $18,543.20

Shares Owned: 203,040

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-21	Yoshiyama, Annie	Officer	SVP, Finance	Direct	Sale	9,586	2.31	$22,143.66	124,517	4
2026-03-31	Beneski, Benjamin Machina…	Officer	SVP, Chief Technical Officer	Direct	Sale	2,867	2.50	$7,167.50	195,338	4
2026-03-16	Beneski, Benjamin Machina…	Officer	SVP, Chief Technical Officer	Direct	Sale	4,835	2.47	$11,942.45	198,205	4
2026-03-16	Chang, David D	Director,Officer	President and CEO	Direct	Sale	47,763	2.47	$117,974.61	5,150,599	4
2026-03-02	Beneski, Benjamin Machina…	Officer	SVP, Chief Technical Officer	Direct	Sale	7,132	2.60	$18,543.20	203,040	4
2026-02-02	Parker, Geoffrey M.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	24,001	1.76	$42,241.76	1,252,795	4
2026-02-02	Douglas, Earl Martin	Officer	SVP, General Counsel	Direct	Sale	22,900	1.76	$40,304.00	564,948	4
2026-02-02	Roberts, Zachary	Officer	EVP of R&D	Direct	Sale	35,700	1.77	$63,189.00	581,166	4
2026-02-02	Yoshiyama, Annie	Officer	SVP, Finance	Direct	Sale	4,167	1.72	$7,167.24	130,322	4
2026-02-02	Chang, David D	Director,Officer	President and CEO	Direct	Sale	95,269	1.80	$171,484.20	5,185,862	4
2026-02-02	Beneski, Benjamin Machina…	Officer	SVP, Chief Technical Officer	Direct	Sale	7,549	1.73	$13,059.77	210,172	4
2026-01-21	Roberts, Zachary	Officer	EVP of R&D	Direct	Sale	26,269	1.56	$40,979.64	616,866	4
2025-11-17	Beneski, Benjamin Machina…	Officer	SVP, Chief Technical Officer	Direct	Sale	786	1.22	$958.92	217,721	4
2025-10-21	Parker, Geoffrey M.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	36,744	1.26	$46,297.44	1,276,796	4
2025-06-10	Messemer, Deborah M.	Director	-	Direct	Sale	36,885	1.42	$52,376.70	107,431	4
2025-04-21	Yoshiyama, Annie	Officer	SVP, Finance	Direct	Sale	9,601	1.41	$13,537.41	130,663	4
2025-03-14	Chang, David D	Director,Officer	President and CEO	Direct	Sale	46,668	1.96	$91,469.28	5,276,569	4
2025-03-14	Beneski, Benjamin Machina…	Officer	SVP, Chief Technical Officer	Direct	Sale	5,488	1.98	$10,866.24	218,507	4
2025-02-18	Messemer, Deborah M.	Director	-	Direct	Sale	13,313	2.43	$32,350.59	144,316	4
2025-02-03	Roberts, Zachary	Officer	EVP of R&D	Direct	Sale	18,832	1.70	$32,014.40	643,135	4
2025-02-03	Chang, David D	Director,Officer	President and CEO	Direct	Sale	46,003	1.68	$77,285.04	5,317,237	4
2025-02-03	Parker, Geoffrey M.	Officer	CHIEF FINANCIAL OFFICER	Direct	Sale	4,361	1.73	$7,544.53	1,301,540	4
2025-02-03	Douglas, Earl Martin	Officer	SVP, General Counsel	Direct	Sale	6,404	1.71	$10,950.84	587,848	4
2025-02-03	Moore, Timothy L.	Officer	Chief Technical Officer	Direct	Sale	14,746	1.71	$25,215.66	250,713	4
2025-01-21	Roberts, Zachary	Officer	EVP of R&D	Direct	Sale	27,199	1.78	$48,414.22	488,054	4
2024-12-09	Messemer, Deborah M.	Director	-	Direct	Sale	9,136	2.18	$19,916.48	157,629	4
2024-12-05	Humer, Franz B	Director	-	Direct	Sale	9,221	2.16	$19,917.36	307,507	4
2024-06-18	Messemer, Deborah M.	Director	-	Direct	Sale	18,641	2.28	$42,501.48	166,765	4
2024-05-30	Humer, Franz B	Director	-	Direct	Sale	11,200	2.34	$26,208.00	255,253	4
2024-05-16	Belldegrun, Arie	Director	-	Indirect	Purchase	1,724,137	2.90	$4,999,997.30	1,724,137	4
2024-01-30	Parker, Geoffrey M.	Officer	CHIEF FINANCIAL OFFICER	Direct	Purchase	190	3.60	$684.00	819,590	4
2023-12-18	Messemer, Deborah M.	Director	-	Direct	Sale	18,640	2.70	$50,328.00	62,456	4
2023-08-07	Mayo, Stephen	Director	-	Direct	Sale	10,000	4.29	$42,900.00	25,328	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

73.35%

Inst. Shares: 176,242,800

Shares Outstanding: 240,290,782

2025-12-31

71.18%

Inst. Shares: 157,034,727

Shares Outstanding: 220,622,669

2025-09-30

70.98%

Inst. Shares: 157,611,069

Shares Outstanding: 222,038,680

2025-06-30

81.31%

Inst. Shares: 178,000,997

Shares Outstanding: 218,929,548

2025-03-31

88.76%

Inst. Shares: 191,156,681

Shares Outstanding: 215,358,619

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	176,242,800	240,290,782	73.35%
2025-12-31	157,034,727	220,622,669	71.18%
2025-09-30	157,611,069	222,038,680	70.98%
2025-06-30	178,000,997	218,929,548	81.31%
2025-03-31	191,156,681	215,358,619	88.76%
2024-12-31	182,895,519	194,811,756	93.88%
2024-09-30	157,346,502	209,188,551	75.22%
2024-06-30	157,836,404	190,026,638	83.06%
2024-03-31	125,853,562	169,128,362	74.41%
2023-12-31	117,381,409	156,931,778	74.80%
2023-09-30	124,644,132	167,649,010	74.35%
2023-06-30	124,544,068	146,795,826	84.84%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Allogene Therapeutics, Inc. (ALLO) — SEC Financial Statements & Analysis

Allogene Therapeutics, Inc. (ALLO) is a biological products, (no diagnostic substances) company. Allogene Therapeutics, Inc. trades on Nasdaq as: ALLO. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Allogene Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.26x, a Price-to-Sales (P/S) ratio of 18861.32x (TTM), a Price-to-Book (P/B) ratio of 1.57x (TTM), at a market cap of $684.17M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.26x
P/S TTM: 18861.32x
P/B TTM: 1.57x
Market Cap: $684.17M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Allogene Therapeutics, Inc. in?

Allogene Therapeutics, Inc. (ALLO) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ALLO's market cap?

Allogene Therapeutics, Inc. (ALLO) has a market capitalization of $684.17M as of 2026-06-30.

What exchange does ALLO trade on?

Allogene Therapeutics, Inc. (ALLO) trades on the Nasdaq.